Cot (P284) Peptide 
Datasheet
COA
MSDS
SHIP
Product Name :
Cot (P284) Peptide Applications :
Blocking Background :
The role of mitogen-activated protein kinases (MAPKs) in cell signaling pathways is well established. The rat gene Tpl-2, for tumor progression locus 2, and the human and mouse homologues c-Cot, for cancer osaka thyroid oncogene, encode a proto-oncogene serine/threonine protein kinase that was shown to play a role in the functional activation of the MAP kinase pathway. Overexpression of Cot induces MAP kinase activation in COS-1 and NIH/3T3 cells. Cot-mediated activation of MAP kinase is inhibited by both Ras N17, a dominant negative mutant of c-H-Ras, and Raf-1s621A, a dominant negative mutant of Raf-1, suggesting that Cot functions upstream of Ras and Raf-1.Other studies have shown that a kinase-negative, dominant negative mutant of Cot partially blocks Ras or Raf-1-induced MAP kinase activation, arguing that Cot functions downstream of Ras and Raf-1. Alternative Name :
CCOT; COT; COT proto oncogene serine/threonine protein kinase; EST; ESTF; Ewing sarcoma transformant; FLJ10486; M3K8; MAP3K 8; MAP3K8; TPL 2; TPL-2; TPL2; Tumor progression locus 2; Swiss-Prot :
P41279 Product :
1 mg/ml in DI water. Purification&Purity :
Synthetic peptide Cot (P284). (Note: the amino acid sequence is proprietary). The purity is > 98%. Storage&Stability :
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. Specificity :
This peptide can be used with studies using BS1074 Cot (P284) pAb.
Cot (P284) Peptide Applications :
Blocking Background :
The role of mitogen-activated protein kinases (MAPKs) in cell signaling pathways is well established. The rat gene Tpl-2, for tumor progression locus 2, and the human and mouse homologues c-Cot, for cancer osaka thyroid oncogene, encode a proto-oncogene serine/threonine protein kinase that was shown to play a role in the functional activation of the MAP kinase pathway. Overexpression of Cot induces MAP kinase activation in COS-1 and NIH/3T3 cells. Cot-mediated activation of MAP kinase is inhibited by both Ras N17, a dominant negative mutant of c-H-Ras, and Raf-1s621A, a dominant negative mutant of Raf-1, suggesting that Cot functions upstream of Ras and Raf-1.Other studies have shown that a kinase-negative, dominant negative mutant of Cot partially blocks Ras or Raf-1-induced MAP kinase activation, arguing that Cot functions downstream of Ras and Raf-1. Alternative Name :
CCOT; COT; COT proto oncogene serine/threonine protein kinase; EST; ESTF; Ewing sarcoma transformant; FLJ10486; M3K8; MAP3K 8; MAP3K8; TPL 2; TPL-2; TPL2; Tumor progression locus 2; Swiss-Prot :
P41279 Product :
1 mg/ml in DI water. Purification&Purity :
Synthetic peptide Cot (P284). (Note: the amino acid sequence is proprietary). The purity is > 98%. Storage&Stability :
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. Specificity :
This peptide can be used with studies using BS1074 Cot (P284) pAb.
Blocking peptide available as BS1074PP